New research unveils role of innate immune system in pancreatic cancer
Researchers from Adelaide University have demonstrated that blocking a specific immune system gene can reduce pancreatic cancer tumor…
High expression of CTDNEP1 gene linked to poorer kidney cancer survival
Renal cell carcinoma (RCC) is the most common form of kidney cancer, accounting for about 90% of kidney…
Five-session SBRT preserves quality of life before pancreatic cancer surgery
Patients preparing for pancreatic cancer surgery maintained better physical function and experienced less fatigue with five treatments of…
National study benchmarks pancreatic cancer surgery outcomes across China
Pancreatic cancer is among the most aggressive malignancies, and in China it accounts for a substantial and rising…
Daraxonrasib shrinks tumours in one-third of lung cancer patients
Revolution Medicines Inc. (NASDAQ: RVMD) has reported encouraging lung cancer results for its experimental cancer pill daraxonrasib. The…
Young Talent Time host Johnny Young dies, aged 79
Young Talent Time host Johnny Young has died aged 79 following a brief battle with pancreatic cancer. “Johnny…
Engineered probiotic bacteria boost immune attack against pancreatic cancer
Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat. One major…
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Red meat intake emerges as a potential pancreatic cancer risk factor
A review of nearly 2 million participants links higher red meat intake to pancreatic cancer risk, while the…
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What’s Next
In late June and early July 2026, Revolution Medicines reported Phase 1/2 data showing that its RAS G12D…
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…